Pharma: Wichtiger Studienerfolg für Krebsimpfstoff: Moderna-Aktie steigt um 90 Prozent
Erstmals hat ein personalisierter Krebsimpfstoff in einer entscheidenden Studie positive Ergebnisse gezeigt. Analysten sprechen von einem wissenschaftlichen Durchbruch.
München – Moderna's stock surged more than 90 percent on Wednesday, hitting its highest level since July 2024 as the company's stock opened on Wall Street. The impressive rise was driven by positive results from a major, approval-relevant study on an mRNA-based cancer vaccine developed jointly with pharma giant Merck. The drug could come to market as early as 2027.
Merck's stock also rose by approximately 8 percent, reaching nearly $146. The collaboration between Merck and Moderna on the cancer vaccine has been ongoing for a decade.
For Moderna, the study's success represents a crucial victory in the race for mRNA-based therapies. The trial was seen as a critical test for the personalized yet expensive treatment approach. The vaccine is tailored to each patient's specific tumor mutations, aiming to train the immune system to recognize and eliminate characteristic cancer markers.
According to Union-Investment-Portfolio-Manager Markus Manns, "The fact that a personalized cancer vaccine can reduce the likelihood of a tumor recurring for the first time is a scientific breakthrough."
Written by urgent.news from Handelsblatt's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
